Genetic Signatures (ASX:GSS) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GSS 주식 개요

Genetic Signatures Limited는 호주, 아시아 태평양, 미주, 유럽, 중동, 이스라엘, 아프리카에서 분자 진단(MDx) 회사로 운영되고 있습니다.

GSS 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 51.1% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Genetic Signatures Limited 경쟁사

Proteomics International Laboratories

ASX:PIQ

AU$115.8m

Trajan Group Holdings

ASX:TRJ

AU$146.1m

Cryosite

ASX:CTE

AU$53.7m

EZZ Life Science Holdings

ASX:EZZ

AU$63.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Genetic Signatures
과거 주가
현재 주가	AU$0.72
52주 최고치	AU$0.85
52주 최저치	AU$0.38
베타	0.14
11개월 변경	-4.61%
3개월 변경 사항	11.54%
1년 변경 사항	42.16%
33년 변화	-38.30%
5년 변화	-46.30%
IPO 이후 변화	49.48%

최근 뉴스 및 업데이트

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

주주 수익률

	GSS	AU Life Sciences	AU 마켓
7D	7.4%	5.0%	0.8%
1Y	42.2%	-10.6%	10.3%

수익률 대 산업: GSS 지난 1년 동안 -10.9 %를 반환한 Australian Life Sciences 산업을 초과했습니다.

수익률 대 시장: GSS 지난 1년 동안 6.7 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is GSS's price volatile compared to industry and market?
GSS volatility
GSS Average Weekly Movement	4.9%
Life Sciences Industry Average Movement	9.3%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.2%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: GSS 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: GSS 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2001	n/a	Neil Gunn	www.geneticsignatures.com

Genetic Signatures Limited는 호주, 아시아 태평양, 미주, 유럽, 중동, 이스라엘 및 아프리카에서 분자 진단(MDx) 회사로 운영되고 있습니다. 이 회사는 EasyScreen이라는 브랜드로 감염병 검출을 위한 실시간 중합효소 연쇄 반응 기반 제품군을 설계 및 제조합니다. 또한 병원 및 병리 실험실에서 다양한 감염성 병원체를 검사할 수 있는 MDx 3Base 플랫폼 기술을 제공합니다.

Genetic Signatures Limited 기본 사항 요약

Genetic Signatures 의 수익과 매출은 시가총액과 어떻게 비교하나요?
GSS 기본 통계
시가총액	AU$156.08m
수익(TTM)	-AU$18.04m
수익(TTM)	AU$15.99m

9.8x

P/S 비율

-8.7x

P/E 비율

GSS 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
GSS 손익 계산서(TTM)
수익	AU$15.99m
수익 비용	AU$9.79m
총 이익	AU$6.20m
기타 비용	AU$24.24m
수익	-AU$18.04m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.084
총 마진	38.79%
순이익 마진	-112.83%
부채/자본 비율	0%

GSS 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

GSS 주식 개요

보상

위험 분석

Genetic Signatures Limited 경쟁사

ASX:PIQ

AU$115.8m

ASX:TRJ

AU$146.1m

ASX:CTE

AU$53.7m

ASX:EZZ

AU$63.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

주주 수익률

가격 변동성

회사 소개

Genetic Signatures Limited 기본 사항 요약

9.8x

-8.7x